Substituted pyrimidines as cyclin-dependent kinase inhibitors

US10988476B2 · kind B2 · utility

Assignee

• Shanghai Pharmaceuticals Holding Co., Ltd. · CN

Inventors

• Guangxin Xia · Shanghai, CN
• Qian Wang · Santa Clara, US
• Chen Shi · Beijing, CN
• Xiong Zhai · Shanghai, CN
• Hui Ge · Zhejiang, CN
• Xuemei LIAO · Shanghai, CN
• Yu MAO · Shanghai, CN
• Zhixiong Xiang · Shanghai, CN
• Yanan HAN · Shanghai, CN
• Guoyong HUO · Shanghai, CN
• Yanjun Liu · Shanghai, CN

Key dates

• Filing date: Apr 15, 2020
• Grant date: Apr 27, 2021
• Expiry date: Apr 15, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention discloses a substituted pyridine compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer and tautomer thereof. The compounds of the present invention are useful in the treatment of cancers.